Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
6(85.7%)
Phase 1
1(14.3%)
7Total
Phase 2(6)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06640972Phase 2Completed

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

Role: lead

NCT00810979Phase 2Completed

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

Role: lead

NCT00562575Phase 2Completed

Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

Role: lead

NCT02434744Phase 2Completed

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT00871936Phase 2Completed

A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

Role: lead

NCT05857566Phase 1Completed

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

Role: lead

NCT00528242Phase 2Completed

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Role: lead

All 7 trials loaded